Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.
about
Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis.Pitfalls in diagnosis with the use of circulating tumor-derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M.Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy.Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report.Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
P2860
Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical characteristics and r ...... wth factor receptor mutations.
@en
Clinical characteristics and r ...... wth factor receptor mutations.
@nl
type
label
Clinical characteristics and r ...... wth factor receptor mutations.
@en
Clinical characteristics and r ...... wth factor receptor mutations.
@nl
prefLabel
Clinical characteristics and r ...... wth factor receptor mutations.
@en
Clinical characteristics and r ...... wth factor receptor mutations.
@nl
P2093
P2860
P1476
Clinical characteristics and r ...... wth factor receptor mutations.
@en
P2093
Hongyu Wang
Jianming Ying
Xingsheng Hu
Xuezhi Hao
Zheng Wang
P2860
P356
10.21147/J.ISSN.1000-9604.2017.01.03
P577
2017-02-01T00:00:00Z